Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Combination Products: US FDA Aims For Limited Two-Application Solutions

Executive Summary

In announcing guidance stating one application generally is sufficient for a combination product, FDA asks for comments on situations where two would be needed.

Related Content

US FDA Again Looks Outside Generic Drugs Office For New Director
Generic Advair's Labeling Variation Stems From Permissible Design Differences, US FDA Says
Keeping Track: FDA Approves First Generic Advair, But Alkermes And Sunovion Land CRLs
Drug/Software Combos Likely Won't Require Pre-Market Review By US FDA
US FDA Preparing For New 'Combination Product Agreement Meetings'
Combo-Product Sponsors Could More Easily Get Device Designation At US FDA
Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts